CompletedPHASE1, PHASE2NCT00708916

Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients

Studying Discoid lupus erythematosus

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: NYU Langone Health
Principal Investigator: Andrew G Franks, Jr., MD, MD
NYU Langone Health
Intervention: CC-10004(drug)
Enrollment: 8 enrolled
Eligibility: 18-65 years · All sexes
Timeline: 2008 – 2010

Study locations (1)

New York University Tisch Hospital, New York, New York, United States

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00708916 on ClinicalTrials.gov

Other trials for Discoid lupus erythematosus

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE2NCT06261021
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
Innovaderm Research Inc.

See all trials for Discoid lupus erythematosus →

← Back to all trials